Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3435 - Clinical manifestations and prognostic factors of bone metastasis in colorectal cancer

Date

09 Sep 2017

Session

Poster display session

Presenters

You Jin Chun

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

Y.J. Chun, S.W. Lee, J.H. Kim, E. Choe, H.S. Park, S.H. Beom, S.J. Shin, J.B. Ahn

Author affiliations

  • Medical Oncology, Yonsei Cancer Center Yonsei University, 6273 - Seoul/KR
More

Resources

Abstract 3435

Background

Bone metastasis from colorectal cancer (CRC) is known as poor prognostic factor. However, the clinical manifestations and outcomes of CRC with bone metastasis are uncertain.

Methods

CRC with bone metastasis were searched from January 2006 to April 2016, and bone metastasis was diagnosed by plain x-ray, computed tomography (CT), magnetic resonance image (MRI), whole body bone scan (WBBS) or positron emission tomography (PET). Clinical data including site of bone metastasis, visceral metastasis, laboratory finding at diagnosis of bone metastasis, and K-ras mutation were reviewed. Time to event endpoint was analyzed by Kaplan-Meier survival curves for overall survival (OS).

Results

Of 12,005 CRC patients, 321 (2.7%) had bone metastasis. Colon cancer (58.5%) is more than rectal cancer (41.5%), and pattern of metachronous bone metastasis was 166 (51.7%). Median time to bone metastasis was 28.2 months from diagnosis of CRC in metachronous patients. The most common bone metastasis site was spine (69.5%) and followed by pelvis (52.1%) and long bone (21.6%). At the time of bone metastasis, liver (58.2%), lung (51.5%) and peritoneal (23.8%) metastasis was also observed, and bone only metastasis was 28 (8.5%) patients. High neutrophil-lymphocyte ratio (NLR, ≥3.0), alkaline phosphatase (ALP, ≥123 IU/L) and carcinoembryonic antigen (CEA, ≥5 ng/mL) had significantly correlated with bone only metastasis at a low frequency. Median OS from diagnosis of bone metastasis was 8.0 months (95% CI = 6.8-9.2). Patients with bone only metastasis had longer OS (median OS, 19.1 vs. 7.6 months, P 

Conclusions

Bone metastasis of CRC is not a rare event and has a poor prognosis. Bone only metastasis is the most significant prognostic factor and further studies are needed.

Clinical trial identification

Legal entity responsible for the study

Yonsei Cancer Center, Yonsei University Health System

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.